Walgreens CEO Tim Wentworth told CNBC's Jim Cramer that the company is using its stores and brand to bolster its developing health-care business.Walgreens has made significant investments over the past few years to expand beyond a drugstore chain into a large health-care company. Wentworth acknowledged that the company has been closing stores to make sure it has the "right optimized footprint," but challenged the notion that Walgreens has to fully pivot from its stores to pursue its health-care goals."If yo ...

Summary of Walgreens Boots Alliance, Inc. Conference Call Company Overview - **Company**: Walgreens Boots Alliance, Inc. (NASDAQ: WBA) - **Event**: J.P. Morgan 42nd Annual Healthcare Conference - **Date**: January 8, 2024 - **Participants**: - Tim Wentworth - Chief Executive Officer - Manmohan Mahajan - Interim Global Chief Financial Officer - Lisa Gill - J.P. Morgan Healthcare Services Analyst Key Points Company Insights - Tim Wentworth expressed enthusiasm about joining Walgreens, highlighting the brand's trust and reach as unmatched in the industry [3][4] - The company has faced challenges in recent years, but there is a strong reservoir of goodwill among employees and management, which is aiding decision-making and results [5] Strategic Decisions - A significant decision made was cutting the dividend to focus on long-term value creation [6][9] - The company has reduced capital expenditures from over $2 billion to less than $1.4 billion, indicating a more disciplined approach to investments [7][8] - Workforce reductions have been necessary, with difficult decisions made regarding roles that could not be justified [7] Growth Opportunities - The company is focusing on capital-efficient health services expansion, particularly in clinical trials for pharmaceuticals, having signed 25 contracts in two quarters, some worth double-digit millions [10] - There is a strong pipeline from pharmaceutical companies seeking diverse patient populations for trials, leveraging Walgreens' trust and access to patients [10] Management and Talent - The search for a new CFO is ongoing, with the interim CFO performing well [12][13] - The executive team is committed to being based in Chicago to foster collaboration and innovation [14][15] Industry Dynamics - The reimbursement model in retail pharmacy is under pressure, with decreasing reimbursements as a percentage of AWP [17][18] - Walgreens is already being compensated for services like vaccinations and testing, which were previously hard to charge for [19] - The company supports a shift towards cost-plus models but does not require it for profitability [19][20] Consumer Behavior - The state of the consumer is mixed, with a focus on value and loyalty rewards as consumers look to stretch their dollars [42][43] - The company is actively working on private label products, aiming to increase penetration from 19% to 40% over five years [44][46] Challenges and Risks - Shrinkage (theft) is a significant issue, particularly in urban areas, and the company is investing in solutions to address this [48][50] - The company has committed to closing 200 stores, with 100 already closed, as part of ongoing optimization efforts [52][53] Healthcare Services Strategy - Walgreens is focused on its healthcare services business, including partnerships with VillageMD and CareCentrix, which are profitable and expanding [59][60] - The company is exploring additional services that can leverage its engagement platform to improve patient outcomes [63][64] Financial Outlook - For fiscal year 2024, adjusted EBITDA for the healthcare segment is expected to increase by approximately $375 million, driven by VillageMD and other healthcare services [67][68] - The company is working to accelerate profitability within VillageMD, with plans to exit certain markets to focus on core areas [68][70] Future Vision - Tim Wentworth hopes that in a year, stakeholders will appreciate the Walgreens brand's potential to enhance health systems and provider goals [72]

Walgreens Boots Alliance, Inc. (NASDAQ:WBA) J.P. Morgan 42nd Annual Healthcare Conference January 8, 2024 11:15 AM ET Company Participants Tim Wentworth - Chief Executive Officer Manmohan Mahajan - Interim Global Chief Financial Officer Conference Call Participants Lisa Gill - J.P. Morgan Lisa Gill Maybe it's just me. Oh, there we go. Good morning. My name is Lisa Gill, and I'm the healthcare services analyst with J.P. Morgan. It is with great pleasure this morning that I have with me Walgreens Boots Allian ...

DEERFIELD, Ill.--(BUSINESS WIRE)--The Expressions Challenge by Walgreens officially launches today, January 8 and runs through March 31, 2024. What started 15 years ago in Chicago to provide roughly 300 high school teenagers a chance to express themselves through art on HIV and AIDS, is now reaching millions of teenagers across all 50 states of the United States - including Washington DC, Puerto Rico and the US Virgin Islands – and allowing them to express themselves on a variety of issues impacting teens. ...

In an interview, Walgreens chief executive Tim Wentworth said VillageMD and Walgreens have slowed ... [+] the growth of doctor-staffed clinics adjacent to Walgreens drugstores in part because the operators haven’t been able to fill their so-called “panels,” which are a certain number of individual patients under the care of a specific provider.VillageMDWalgreens chief executive’s disclosure last week that VillageMD’s doctor-staffed clinic expansion plan needed to go “on a diet” highlights certain risks in t ...

The owner of Boots could be considering a £7 billion London listing for the high street pharmacy company, reviving exit talks two years after a planned sale fell through. Tim Wentworth, the chief executive officer of Walgreens Boots Alliance Inc (NASDAQ:WBA), revealed “everything is on the table" when it comes to planning the next step for the UK retailer. He added that the US owner is “evaluating all strategic options to drive sustainable long-term shareholder value”. In January 2022, the company placed Bo ...

Walgreens Boots Alliance (WBA -5.12%) got the bad news out early in 2024. The pharmacy company is cutting its dividend by nearly 50%. That ended a streak of 47 years of dividend growth. That reduction will enable Walgreens to retain more cash to fund its growth and strengthen its balance sheet. Here's a look at whether now's the time to buy the beaten-down member of the Dow Jones Industrial Average, which lost 30% of its value last year compared to the iconic index's nearly 14% rise. The end of an eraWalgre ...

Walgreens Boots Alliance (WBA) reported $36.71 billion in revenue for the quarter ended November 2023, representing a year-over-year increase of 10%. EPS of $0.66 for the same period compares to $1.16 a year ago.The reported revenue represents a surprise of +5.10% over the Zacks Consensus Estimate of $34.92 billion. With the consensus EPS estimate being $0.63, the EPS surprise was +4.76%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations ...

Walgreens May Have Sped Its Exit From Dow Industrials With Dividend Cut ...

Walgreens Boots Alliance, Inc. (WBA) delivered adjusted earnings per share (EPS) of 66 cents in first-quarter fiscal 2024, plunging 43.1% from the year-ago quarter’s figure (down 43.7% at constant exchange rate or CER). The figure topped the Zacks Consensus Estimate by 4.8%.GAAP loss per share for first-quarter fiscal 2024 was 8 cents compared with the year-ago quarter’s loss of $4.31.Total SalesWalgreens Boots recorded total sales of $36.71 billion in the fiscal first quarter, up 9.9% year over year and 8. ...